Page 274 - Read Online

Page 10 of 11 Vasefi et al. Vessel Plus 2020;4:24 I http://dx.doi.org/10.20517/2574-1209.2020.16

2009;387:407-15.
69. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, et al. Alzheimer’s beta-amyloid peptides compete for insulin binding to
the insulin receptor. J Neurosci 2002;22:RC221.
70. Minano-Molina AJ, Espana J, Martin E, Barneda-Zahonero B, Fado R, et al. Soluble oligomers of amyloid-beta peptide disrupt membrane
trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction. J Biol
Chem 2011;286:27311-21.
71. Liu H, Saffi GT, Vasefi MS, Choi Y, Kruk JS, et al. Amyloid-beta inhibits PDGFbeta receptor activation and prevents PDGF-BBInduced
neuroprotection. Curr Alzheimer Res 2018;15:618-27.
72. Vasefi MS, Kruk JS, Heikkila JJ, Beazely MA. 5-Hydroxytryptamine type 7 receptor neuroprotection against NMDA-induced
excitotoxicity is PDGFbeta receptor dependent. J Neurochem 2013;125:26-36.
73. Paul G, Sullivan AM. Trophic factors for Parkinson’s disease: where are we and where do we go from here? Eur J Neurosci
2019;49:440-52.
74. Tome D, Fonseca CP, Campos FL, Baltazar G. Role of neurotrophic factors in Parkinson’s disease. Curr Pharm Des 2017;23:809-38.
75. Lue LF, Schmitz CT, Snyder NL, Chen K, Walker DG, et al. Converging mediators from immune and trophic pathways to identify
Parkinson disease dementia. Neurol Neuroimmunol Neuroinflamm 2016;3:e193.
76. Cabezas R, Avila MF, Gonzalez J, El-Bacha RS, Barreto GE. PDGF-BB protects mitochondria from rotenone in T98G cells. Neurotox
Res 2015;27:355-67.
77. Cabezas R, Vega-Vela NE, Gonzalez-Sanmiguel J, Gonzalez J, Esquinas P, et al. PDGF-BB preserves mitochondrial morphology,
attenuates ROS production, and upregulates neuroglobin in an astrocytic model under rotenone insult. Mol Neurobiol 2018;55:3085-95.
78. Miyazaki I, Asanuma M. Therapeutic strategy of targeting astrocytes for neuroprotection in Parkinson’s disease. Curr Pharm Des
2017;23:4936-47.
79. Cabezas R, Baez-Jurado E, Hidalgo-Lanussa O, Echeverria V, Ashrad GM, et al. Growth factors and neuroglobin in astrocyte protection
against neurodegeneration and oxidative stress. Mol Neurobiol 2019;56:2339-51.
80. Okada T, Hirai C, Badawy SMM, Zhang L, Kajimoto T, et al. Impairment of PDGF-induced chemotaxis by extracellular alpha-synuclein
through selective inhibition of Rac1 activation. Sci Rep 2016;6:37810.
81. Tang Z, Arjunan P, Lee C, Li Y, Kumar A, et al. Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by
regulating GSK3beta phosphorylation. J Exp Med 2010;207:867-80.
82. Shah BH, Catt KJ. GPCR-mediated transactivation of RTKs in the CNS: mechanisms and consequences. Trends Neurosci 2004;27:48-53.
83. Kruk JS, Kouchmeshky A, Grimberg N, Rezkella M, Beazely MA. Transactivation of receptor tyrosine kinases by dopamine receptors.
Dopamine Receptor Technologies. New York, NY: Springer New York; 2015. pp. 211-27.
84. Gill RS, Hsiung MS, Sum CS, Lavine N, Clark SD, et al. The dopamine D4 receptor activates intracellular platelet-derived growth factor
receptor beta to stimulate ERK1/2. Cell Signal 2010;22:285-90.
85. Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC. Angiotensin II induces transactivation of two different populations of the platelet-
derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J Biol Chem 2000;275:15926-32.
86. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, et al. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin
receptor subtype. J Biol Chem 1993;268:18200-4.
87. Thomas DR, Hagan JJ. 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:81-90.
88. Speranza L, Labus J, Volpicelli F, Guseva D, Lacivita E, et al. Serotonin 5-HT7 receptor increases the density of dendritic spines and
facilitates synaptogenesis in forebrain neurons. J Neurochem 2017;141:647-61.
89. Vasefi MS, Kruk JS, Liu H, Heikkila JJ, Beazely MA. Activation of 5-HT7 receptors increases neuronal platelet-derived growth factor
beta receptor expression. Neurosci Lett 2012;511:65-9.
90. Samarajeewa A, Goldemann L, Vasefi MS, Ahmed N, Gondora N, et al. 5-HT7 receptor activation promotes an increase in TrkB receptor
expression and phosphorylation. Front Behav Neurosci 2014;8:391.
91. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, et al. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to
inhibit NMDA receptor transmission. Neuron 2002;35:1111-22.
92. Vasefi MS, Yang K, Li J, Kruk JS, Heikkila JJ, et al. Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially
alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons. Mol Brain 2013;6:24.
93. Kanki H, Sasaki T, Matsumura S, Yokawa S, Yukami T, et al. beta-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial
function via PDGF-beta in stroke. Cell Death Dis 2019;10:100.
94. Abassi M, Morawski BM, Nakigozi G, Nakasujja N, Kong X, et al. Cerebrospinal fluid biomarkers and HIV-associated neurocognitive
disorders in HIV-infected individuals in Rakai, Uganda. J Neurovirol 2017;23:369-75.
95. Jung KH, Chu K, Lee ST, Bahn JJ, Jeon D, et al. Multipotent PDGFRbeta-expressing cells in the circulation of stroke patients. Neurobiol
Dis 2011;41:489-97.
96. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s
disease. PLoS One 2012;7:e29868.
97. Rocha de Paula M, Gomez Ravetti M, Berretta R, Moscato P. Differences in abundances of cell-signalling proteins in blood reveal novel
biomarkers for early detection of clinical Alzheimer’s disease. PLoS One 2011;6:e17481.
98. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, et al. Novel CSF biomarkers for Alzheimer’s disease and mild cognitive
impairment. Acta Neuropathol 2010;119:669-78.
99. Mahlknecht P, Stemberger S, Sprenger F, Rainer J, Hametner E, et al. An antibody microarray analysis of serum cytokines in